

May 8, 2025

BrightPath to Present the Data of Manufacturing Process of iPS Cell-derived BCMA CAR-iNKT Cells (BP2202) at ASGCT 2025

Tokyo, Japan – May 8, 2025/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, today announced that the Company will present data on GMP-compliant manufacturing process develop for generating iPS cell-derived BCMA CAR-iNKT cells from clinical-grade iPSCs at the American Society of Gene and Cell Therapy 28th Annual Meeting (ASGCT 2025, May 13-17, New Orleans). Summary of the abstract and the electronic poster will be posted on the website of BrightPath after ASGCT 2025 is held.

Title:

Generation of functional BCMA CAR-iNKT cells from clinical-grade iPSCs via a GMP-compliant manufacturing process with capacity for linear scale-up
(Abstract Number 812)

Date & Time: 6:00 p.m. – 7:30 p.m. CDT on May 13, 2025

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies, currently in clinical trials, and immunomodulatory antibodies.

For more information, visit www.brightpathbio.com/English/

Investor and Media Contact:

irpr@brightpathbio.com

www.brightpathbio.com/English/